Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-021-06115-9
Abstract: Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-HER2… read more here.
Keywords: therapy; her2; her2 therapy; breast cancer ... See more keywords
Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.19
Abstract: ...was active in these patients, two-thirds of whom had received prior anti-HER2 therapy Outcomes of patients with HER2+ breast or gastroesophageal cancer are greatly improved with standard anti‐HER2 antibody therapies, principally trastuzumab; however, resistance and… read more here.
Keywords: therapy; anti her2; her2 therapy; cancer ... See more keywords
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.1034
Abstract: 1034 Background: Anti-HER2 therapy has improved survival in HER2+ MBC. Yet, large patient cohorts with no evidence of disease (NED) with long-term follow up are incompletely described in the literature. We evaluated the clinical characteristics… read more here.
Keywords: mbc; anti her2; disease; her2 therapy ... See more keywords
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0241775
Abstract: Purpose The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear.… read more here.
Keywords: her2 equivocal; anti her2; asco cap; her2 negative ... See more keywords
Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.852809
Abstract: Objective This study aims to assess the performance of machine learning (ML)-based contrast-enhanced CT radiomics analysis for predicating the efficacy of anti-HER2 therapy for patients with liver metastases from breast cancer. Methods This retrospective study… read more here.
Keywords: efficacy anti; validation; value; phase ... See more keywords
Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study
Sign Up to like & getrecommendations! Published in 2024 at "Cancers"
DOI: 10.3390/cancers16244188
Abstract: Simple Summary Data are lacking on the optimal neoadjuvant systemic treatment of patients with hormone receptor and HER2 positive breast cancer who are unfit for the combination of chemotherapy and anti-HER2 therapy. A nationwide series… read more here.
Keywords: breast cancer; anti her2; her2; net anti ... See more keywords